ALG.APV-527

About Aptevo Therapeutics

Aptevo Therapeutics is a Seattle-based biotech focused on developing next-generation, multi-specific antibody therapies for cancer. The company's core strategy is its proprietary protein engineering platform, which enables the rational design of T-cell engagers and co-stimulatory molecules with tunable properties to potentially overcome limitations of current immunotherapies. Its most advanced asset, mipletamig (APVO436), is a CD3xCD123 bispecific in Phase 1/2 development for acute myeloid leukemia (AML). Operating as a lean, publicly-traded entity, Aptevo aims to advance its broad, early-stage pipeline through clinical validation and strategic partnerships.

About alligator-bioscience-ab

Alligator Bioscience is a clinical-stage biotech focused on developing tumor-directed antibody therapies for cancer. Its core strategy is built on proprietary platforms like ALiCE® and RUBY™ to generate highly specific, next-generation immuno-oncology drugs. The company's most advanced program, mitazalimab (a CD40 agonist), is in a pivotal Phase 2/3 trial for metastatic pancreatic ductal adenocarcinoma (PDAC), representing a significant near-term value inflection point. Alligator operates as an R&D-centric organization, advancing its pipeline through internal development and strategic partnerships.

Therapeutic Areas